Abstract:Endoscopy is commonly used for diagnosis and management of patients with inflammatory bowel disease (IBD); however, it is costly, invasive and has known risks of complications. Faecal calprotectin (FC) is a non-invasive biomarker of intestinal inflammation and is highly correlated with endoscopic disease activity. The use of FC testing is not well understood in IBD in a real-world setting. This retrospective cohort study examined the use of FC and subsequent endoscopy for patients who had an FC test vs. those who never had an FC test in Crohn’s disease (CD) and ulcerative colitis (UC) separately. The study, included adult patients (≥18years) with ≥2 diagnosis codes of UC or CD from 2008–2015 in the US Truven Health MarketScan® Commercial Databases. Date of first FC test in the database was defined as index date for FC cohorts; a randomly selected date with an IBD diagnosis claim was defined as index date for non-FC cohorts. Patients were required to have continuous eligibility for ≥6 months before and ≥12 months after index date. Patients in each cohort were propensity score matched (1:1) to have comparable baseline characteristics. Proportions of patients who received endoscopy and average number of subsequent endoscopy procedures performed in CD and UC patients were summarised annually over 3 years post-index date. Trend analyses were conducted to examine whether endoscopy use was different between FC and non-FC cohorts over time. Among 47709 CD patients identified, 981 (2.06%) had FC testing; among 61276 UC patients identified, 522 (0.85%) had FC testing. Of patients who had FC testing, the proportion of subsequent FC testing decreased from year 1 to year 3 post-index date (UC: 22%, 13%, 10%; CD: 17%, 14%, 9%). After matching, FC and non-FC cohorts were comparable in baseline characteristics, including healthcare resource utilisation. Over the 3-year follow-up, trends of endoscopy use differed significantly between FC and non-FC cohorts. FC cohorts’ endoscopy use decreased over the 3-year follow-up (UC: 52%, 32%, 30%; CD: 47%, 29%, 26%), and proportions reduced to less than one-third starting year 2. However, consistently over one-third of patients used endoscopy in non-FC cohorts (UC: 36%, 35%, 38%; CD: 33%, 35%, 33%). Similarly, average numbers of endoscopies per patient decreased in FC cohorts over time (UC: 0.67, 0.40, 0.36; CD: 0.57, 0.36, 0.33) vs. a consistent use in non-FC cohorts (UC: 0.42, 0.46, 0.47; CD: 0.41, 0.46, 0.42). The 3-year trends were significantly different between FC and non-FC cohorts (p < 0.001). Implementation of FC testing has been limited in US clinical practice. Patients with FC testing had reduced endoscopy use over time vs. patients who never received FC testing.

Fecal calprotectin as an alternative to ulcerative colitis endoscopic index of severity to predict the response to corticosteroids of acute severe ulcerative colitis: A prospective observational study

Corticosteroid Therapy in Ulcerative Colitis: Clinical Response and Predictors.

The value of fecal calprotectin in predicting endoscopic activity and severity of ulcerative colitis

The correlation between fecal calprotectin, simple clinical colitis activity index and biochemical markers in ulcerative colitis during high-dose steroid treatment

Diagnostic Performance of a Fecal Calprotectin Assay as a Biomarker for Mayo Endoscopic Subscore in Ulcerative Colitis: Result From a Tertiary Referral Center

Fecal Calprotectin: A Novel Predictor of Ulcerated Esophageal Injury after Atrial Fibrillation Catheter Ablation.

P576 Fecal calprotectin could predict clinical and endoscopic response to ustekinumab therapy

Use of the Ulcerative Colitis Endoscopic Index of Severity and Mayo Endoscopic Score for Predicting the Therapeutic Effect of Mesalazine in Patients with Ulcerative Colitis

Fecal Calprotectin in Predicting Relapse of Inflammatory Bowel Diseases: A Meta-Analysis of Prospective Studies

Can Fecal Calprotectin Accurately Identify Histological Activity of Ulcerative Colitis? A Meta-Analysis.

Fecal calprotectin diagnostic level gradient along the small bowel in patients with Crohn's disease

Fecal Calprotectin For Evaluating Postoperative Recurrence Of Crohn'S Disease: A Meta-Analysis Of Prospective Studies

P412 Faecal Calprotectin as a predictor of endoscopic and histologic remission in patients with Ulcerative Colitis

Intestinal ultrasonography and fecal calprotectin for monitoring inflammation of ileal Crohn’s disease: two complementary tests

P641 Faecal calprotectin determines non-response to corticosteroids in patients with immune checkpoint inhibitor colitis

P869 Deep ulcers in acute Ulcerative Colitis at index endoscopy predict corticosteroid resistance

P275 Fecal calprotectin, intestinal ultrasound, and their combination for the diagnosis of Crohn’s disease

Fecal Calprotectin for Evaluating Postoperative Recurrence of Crohnʼs Disease

Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis

P561 Ulcerative Colitis Endoscopic Index of Severity (UCEIS) and Mayo Endoscopic Score (MES) in Predicting the Therapeutic Effect of Mesalazine in UC Patients

Real-World Use Of Faecal Calprotectin Testing In Patients With Inflammatory Bowel Disease